Page 4 - Director Wayne News Today

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective cut by Barclays from $40.00 to $18.00 in a report published on Monday, Marketbeat.com reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the stock. Chardan Capital restated a buy rating and set […]

HC Wainwright reaffirmed their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research note published on Friday, Benzinga reports. HC Wainwright currently has a $38.00 price target on the biotechnology company’s stock. Other analysts also recently issued reports about the stock. Truist Financial reaffirmed a buy rating and set a […]

Truist Financial reaffirmed their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research note published on Friday morning, Benzinga reports. The firm currently has a $17.00 price objective on the biotechnology company’s stock. IOVA has been the subject of a number of other research reports. Stifel Nicolaus reduced their price […]

Mizuho restated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research note published on Friday, Benzinga reports. Mizuho currently has a $30.00 price objective on the biotechnology company’s stock. Several other brokerages have also commented on IOVA. HC Wainwright reaffirmed a buy rating and issued a $38.00 price target […]

HC Wainwright reiterated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $38.00 price objective on the biotechnology company’s stock. A number of other analysts have also issued reports on the stock. Wells Fargo & Company […]

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw strong trading volume on Monday following insider buying activity. 3,266,771 shares traded hands during trading, a decline of 35% from the previous session’s volume of 5,031,225 shares.The stock last traded at $5.76 and had previously closed at $5.27. Specifically, Director Wayne P. Rothbaum acquired […]

Herald Investment Management Ltd purchased a new position in shares of Arteris, Inc. (NASDAQ:AIP – Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 237,182 shares of the company’s stock, valued at approximately $1,003,000. Herald Investment Management Ltd owned about 0.67% of Arteris at the […]

Arteris, Inc. (NASDAQ:AIP – Get Rating) Director Wayne C. Cantwell sold 17,359 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $7.33, for a total transaction of $127,241.47. Following the transaction, the director now directly owns 226,623 shares in the company, valued at $1,661,146.59. […]

Arteris, Inc. (NASDAQ:AIP – Get Rating) Director Wayne C. Cantwell sold 17,359 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $7.33, for a total value of $127,241.47. Following the completion of the transaction, the director now directly owns 226,623 shares […]

Arteris, Inc. (NASDAQ:AIP – Get Rating) Director Wayne C. Cantwell sold 17,359 shares of Arteris stock in a transaction on Friday, June 9th. The stock was sold at an average price of $7.33, for a total value of $127,241.47. Following the transaction, the director now directly owns 226,623 shares of the company’s stock, valued at […]